The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents
Abstract
CONTEXT: Clinical trials that have excluded patients at high risk for cardiac events have led to commercial labeling approval of drug-eluting stents; nevertheless, such high-risk patients commonly undergo stent placement in clinical practice. The degree to which they experience cardiac events at a higher rate than non-high-risk patients is unclear. OBJECTIVE: To assess the rates of major adverse cardiac events during the index admission and 1 year after the implantation of drug-eluting stents in patients with high-risk angiographic and clinical features. DESIGN, SETTING, AND PATIENTS: From July 2004 to September 2005, consecutive patients who underwent attempted stent placement at 42 different hospitals throughout the United States were enrolled in a prospective multicenter registry. We analyzed outcomes of 3323 patients who received at least 1 drug-eluting stent for a reason other than acute ST-segment elevation myocardial infarction. The study population was divided into 2 groups based on presence of at least 1 of 9 off-label characteristics based on the current US Food and Drug Administration-approved indications for sirolimus- and paclitaxel-eluting stents. MAIN OUTCOME MEASURES: The composite clinical outcomes of death, myocardial infarction, or target vessel revascularization during the index admission and death, myocardial infarction, or target lesion revascularization at 1 year were evaluated. RESULTS: Of the 3323 patients, 1817 (54.7%) had at least 1 off-label characteristic. During the index hospitalization, the composite clinical outcome occurred in 198 (10.9%) of patients in the off-label group and 76 (5.0%) of patients in the on-label group (adjusted odds ratio, 2.32; 95% confidence interval [CI], 1.75-3.07; P<.001). At 1 year, the composite clinical outcome occurred more often in the off-label group compared with the on-label group; 309 (17.5%) vs 131 (8.9%) (adjusted hazard ratio [HR], 2.16; 95% CI, 1.74-2.67; P<.001). Stent thrombosis also occurred more frequently among patients in the off-label group during the initial hospitalization (8 [0.4%] vs 0) and at 1 year: 29 (1.6%) vs 13 (0.9%), adjusted HR, 2.29 (95% CI, 1.02-5.16; P = .05). CONCLUSIONS: Compared with on-label use, off-label use of drug-eluting stents is associated with a higher rate of adverse outcomes during the index admission and at 1 year. Stent thrombosis occurred predominantly in patients who underwent off-label drug-eluting stent implantation. Clinicians should be cautious about extrapolating the benefits of drug-eluting stents over bare-metal stents observed in randomized clinical trials to higher-risk clinical settings that have not been assessed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa035071 · Cited by 4,224
A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease
Stone, G. W., Ellis, S. G., Cox, D. A., Hermiller, J., O'Shaughnessy, C., Mann, J. T., Turco, M., Caputo, R., Bergin, P., Greenberg, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032441 · Cited by 2,749
Daemen, J., Wenaweser, P., Tsuchida, K., Abrecht, L., Vaina, S., Morger, C., Kukreja, N., Jüni, P., Sianos, G., Hellige, G., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60314-6 · Cited by 1,757
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Ellis, S. G., Vandormael, M. G., Cowley, M. J., DiSciascio, G., Deligonul, U., Topol, E. J., & Bulle, T. M. (1990) · Circulation · doi:10.1161/01.cir.82.4.1193 · Cited by 1,350
Late Clinical Events After Clopidogrel Discontinuation May Limit the Benefit of Drug-Eluting Stents
Pfisterer, M., Brunner-La Rocca, H. P., Buser, P. T., Rickenbacher, P., Hunziker, P., Mueller, C., Jeger, R., Bader, F., Osswald, S., & Kaiser, C. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.026 · Cited by 1,303
Long-Term Outcomes with Drug-Eluting Stents versus Bare-Metal Stents in Sweden
Lagerqvist, B., James, S. K., Stenestrand, U., Lindbäck, J., Nilsson, T., & Wallentin, L. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067722 · Cited by 1,197
Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation
Eisenstein, E. L., Anstrom, K. J., Kong, D. F., Shaw, L. K., Tuttle, R. H., Mark, D. B., Kramer, J. M., Harrington, R. A., Matchar, D. B., Kandzari, D. E., et al. (2007) · JAMA · doi:10.1001/jama.297.2.joc60179 · Cited by 870
Spertus, J. A., Kettelkamp, R., Vance, C., Decker, C., Jones, P. G., Rumsfeld, J. S., Messenger, J. C., Khanal, S., Peterson, E. D., Bach, R. G., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.618066 · Cited by 854
Self-citationNordmann, A. J., Briel, M., & Bucher, H. C. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl282 · Cited by 480
Cited by
Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention
Tonino, P. A. L., De Bruyne, B., Pijls, N. H. J., Siebert, U., Ikeno, F., van `t Veer, M., Klauss, V., Manoharan, G., Engstrøm, T., Oldroyd, K. G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0807611 · Cited by 4,260
Writing Committee Members, Levine, G. N., Bates, E. R., Blankenship, J. C., Bailey, S. R., Bittl, J. A., Cercek, B., Chambers, C. E., Ellis, S. G., Guyton, R. A., et al. (2011) · Circulation · doi:10.1161/cir.0b013e31823ba622 · Cited by 3,289
Moll, F. L., Powell, J. T., Fraedrich, G., Verzini, F., Haulon, S., Waltham, M., van Herwaarden, J. A., Holt, P. J. E., van Keulen, J. W., Rantner, B., et al. (2011) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2010.09.011 · Cited by 1,468
Pijls, N. H. J., Fearon, W. F., Tonino, P. A. L., Siebert, U., Ikeno, F., Bornschein, B., van't Veer, M., Klauss, V., Manoharan, G., Engstrøm, T., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.04.012 · Cited by 1,158
Scientific evidence underlying the ACC/AHA clinical practice guidelines.
Tricoci, P. (2009) · JAMA · doi:10.1001/jama.2009.205 · Cited by 908
Metadata
- Authors
- Win, H. K., Caldera, A. E., Maresh, K., Lopez, J., Rihal, C. S., Parikh, M. A., Granada, J. F., Marulkar, S., Nassif, D., Cohen, D. J., Kleiman, N. S., & EVENT Registry Investigators, F. T.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2007-05-09
- Volume
- 297
- Issue
- 18
- Pages
- 2001
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1976394282
- Cited by
- 343
- References
- 14
- FWCI
- 57.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents. https://app.cochat.ai/papers/10.1001/jama.297.18.2001
- The paper
- Win, H. K., Caldera, A. E., Maresh, K., Lopez, J., Rihal, C. S., Parikh, M. A., Granada, J. F., Marulkar, S., Nassif, D., Cohen, D. J., Kleiman, N. S., & EVENT Registry Investigators, F. T. (2007). Clinical Outcomes and Stent Thrombosis Following Off-Label Use of Drug-Eluting Stents. JAMA. https://doi.org/10.1001/jama.297.18.2001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.